Clearmind Medicine granted U.S. patent for binge behavior regulators

Clearmind Medicine Inc. (CMND) — Clearmind Medicine was granted U.S.

Patent No. 12,350,242, titled 'Binge Behavior Regulators,' covering compositions and methods using its proprietary molecule MEAI (5-methoxy-2-aminoindane) to regulate binge behaviors such as excessive drinking, eating, and gambling. The grant strengthens the intellectual property protecting Clearmind's lead platform, which is being studied for alcohol use disorder. Expanded IP is a value driver for the small-cap developer as it advances its clinical program.

Source: manilatimes.net

For the rest of that week's sector news, read our week in review.